Egetis Therapeutics ABPDPHF 24 PS Ratio is 35.29 as of Jun. 24, 2026, which is 24% above its 10-year median of 28.36. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 937 Biotechnology companies, Egetis Therapeutics AB ranks worse than 73.75% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Egetis Therapeutics AB's share price is $0.6353.
Egetis Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02. Hence, Egetis Therapeutics AB's PS Ratio for today is 35.29.
The historical rank and industry rank for Egetis Therapeutics AB's PS Ratio or its related term are showing as below:
PDPHF'
s PS Ratio Range Over the Past 10 Years
Min: 3.03 Med: 28.36 Max: 5846.98
Current: 31.69
During the past 13 years, Egetis Therapeutics AB's highest PS Ratio was 5846.98. The lowest was 3.03. And the median was 28.36.
PDPHF's PS Ratio is ranked worse than 73.75% of 937
companies
in the Biotechnology industry
Industry Median: 9.36
vs PDPHF: 31.69
Egetis Therapeutics AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Egetis Therapeutics AB was 15.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -16.80% per year.
During the past 13 years, Egetis Therapeutics AB's highest 3-Year average Revenue per Share Growth Rate was 30.00% per year. The lowest was -57.10% per year. And the median was -18.65% per year.
Back to Basics: PS Ratio
Egetis Therapeutics AB (OTCPK:PDPHF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Egetis Therapeutics AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Egetis Therapeutics AB's Share Price of today is $0.6353. Egetis Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Egetis Therapeutics AB (PDPHF) has a PS Ratio of 35.29 as of Jun. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Egetis Therapeutics AB and its competitors. This is 24% above median its historical median of 28.36. Over the past decade, Egetis Therapeutics AB's PS Ratio has ranged from 3.03 to 5,846.98. According to the industry distribution chart, Egetis Therapeutics AB ranks #691 out of 937 companies in the Biotechnology industry, placing it in the top 73.7%.
Is Egetis Therapeutics AB's PS Ratio too high?
Egetis Therapeutics AB's current PS Ratio of 35.29 is 24% above median its 10-year median of 28.36. Over the past 10 years, this metric has ranged from a low of 3.03 to a high of 5,846.98. The Biotechnology industry median PS Ratio is 9.36. Egetis Therapeutics AB's value of 35.29 is 277% above this industry median. Based on the distribution chart, Egetis Therapeutics AB ranks #691 out of 937 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #691 out of 937 companies for PS Ratio. This places Egetis Therapeutics AB in the lower half of its industry. The industry median PS Ratio is 9.36. Egetis Therapeutics AB's value of 35.29 is 277% above this benchmark. Historically, Egetis Therapeutics AB's own PS Ratio has ranged from 3.03 to 5,846.98 over the past decade. While the company's 10-year median is 28.36 vs. the industry median of 9.36, Egetis Therapeutics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.36, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egetis Therapeutics AB's current PS Ratio of 35.29 is 277% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current PS Ratio is 35.29, which is 24% above median its own 10-year median of 28.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current PS Ratio is 35.29, which is 24% above median its 10-year median of 28.36 and 277% above the Biotechnology industry median of 9.36. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current PS Ratio is 35.29 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued.
The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64.
GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.
Key valuation signals for PDPHF:
PS Ratio: 35.29 (24% above median its 10-year median of 28.36)
GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
Industry Position: 277% above the Biotechnology median (#691 of 937)
No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score
Get the complete analysis for PDPHF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDPHF has been successfully added to your 
